1xbet 등록., Ltd.

Pharmaceuticals

November 18, 2010

1xbet 등록^®1xbet 등록, Based on Evidences in Public Domain

1xbet 등록., Ltd. today announced that it has applied for regulatory approval in Japan for an additional indication of L-Cartin^®tablets (nonproprietary name: levocarnitine chloride) 1xbet 등록, based on the evidences in the public domain.

Latest Pharmaceutical Business related News Releases

30 SEP 2024

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay 1xbet 등록 Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^®hematological malignancies gene panel test approved in Japan -

24 SEP 2024

1xbet 등록 Obtains Additional Indication for Rexulti^®in Japan as an Adjunctive Treatment 1xbet 등록 Agitation Associated with Dementia due to Alzheimer's Disease

1xbet 보너스 코드

1xbet 등록 Receives Approval in Japan for Lupkynis^®as a Treatment 1xbet 등록 Lupus Nephritis

Most Recent Releases

1xbet 등록., Ltd.

1xbet 등록®1xbet 등록, Based on Evidences in Public Domain

HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay 1xbet 등록 Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight®hematological malignancies gene panel test approved in Japan -

1xbet 등록 Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment 1xbet 등록 Agitation Associated with Dementia due to Alzheimer's Disease

1xbet 등록 Receives Approval in Japan for Lupkynis®as a Treatment 1xbet 등록 Lupus Nephritis

1xbet 등록^®1xbet 등록, Based on Evidences in Public Domain

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay 1xbet 등록 Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^®hematological malignancies gene panel test approved in Japan -

1xbet 등록 Obtains Additional Indication for Rexulti^®in Japan as an Adjunctive Treatment 1xbet 등록 Agitation Associated with Dementia due to Alzheimer's Disease

1xbet 등록 Receives Approval in Japan for Lupkynis^®as a Treatment 1xbet 등록 Lupus Nephritis